On September 8, 2020 NeuBase Therapeutics, Inc. (NASDAQ: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, reported that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference, as well as participate in a fireside chat at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, which are both being held in September 2020 (Press release, NeuBase Therapeutics, SEP 8, 2020, View Source [SID1234564733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:
Event: H.C. Wainwright 22nd Annual Global Investment Conference (virtual)
Format: Presentation
Date: Wednesday, September 16TH
Time: 1:30 p.m. ET
Location: Webcast Link – or at the company’s website (click here)


Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (virtual)
Format: Fireside Chat
Date: Wednesday, September 23RD
Time: 10:00 a.m. ET
Location: Webcast Link – or at the company’s website (click here)